In 1987, the U.S. Food and Drug Administration (FDA) announced revised regulations regarding Expanded Access (EA) to investigational drugs. Revised regulations regarding EA access to investigational drugs were published in 2009, with revised guidance for industry update as recently as October 2017.

Investigational drug regulations were revised to expand access to experimental drugs for patients with serious diseases with no alternative therapies.